332 related articles for article (PubMed ID: 19652553)
1. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.
Zhang Z; Sun H; Dai H; Walsh RM; Imakura M; Schelter J; Burchard J; Dai X; Chang AN; Diaz RL; Marszalek JR; Bartz SR; Carleton M; Cleary MA; Linsley PS; Grandori C
Cell Cycle; 2009 Sep; 8(17):2756-68. PubMed ID: 19652553
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance.
Yang W; Wei J; Guo T; Shen Y; Liu F
Exp Cell Res; 2014 Aug; 326(1):22-35. PubMed ID: 24930954
[TBL] [Abstract][Full Text] [Related]
3. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression.
Yang H; Li TW; Peng J; Tang X; Ko KS; Xia M; Aller MA
Gastroenterology; 2011 Jul; 141(1):378-88, 388.e1-4. PubMed ID: 21440549
[TBL] [Abstract][Full Text] [Related]
4. Of Myc and Mnt.
Hooker CW; Hurlin PJ
J Cell Sci; 2006 Jan; 119(Pt 2):208-16. PubMed ID: 16410546
[TBL] [Abstract][Full Text] [Related]
5. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
6. Mnt-Max to Myc-Max complex switching regulates cell cycle entry.
Walker W; Zhou ZQ; Ota S; Wynshaw-Boris A; Hurlin PJ
J Cell Biol; 2005 May; 169(3):405-13. PubMed ID: 15866886
[TBL] [Abstract][Full Text] [Related]
7. Chromatin dynamics at the hTERT promoter during transcriptional activation and repression by c-Myc and Mnt in Xenopus leavis oocytes.
Wahlström T; Belikov S; Arsenian Henriksson M
Exp Cell Res; 2013 Dec; 319(20):3160-9. PubMed ID: 23860446
[TBL] [Abstract][Full Text] [Related]
8. Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network.
Bindra RS; Glazer PM
Cancer Lett; 2007 Jul; 252(1):93-103. PubMed ID: 17275176
[TBL] [Abstract][Full Text] [Related]
9. The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells.
Lafita-Navarro MC; Liaño-Pons J; Quintanilla A; Varela I; Blanco R; Ourique F; Bretones G; Aresti J; Molina E; Carroll P; Hurlin P; Romero OA; Sanchez-Céspedes M; Eisenman RN; Delgado MD; León J
J Biol Chem; 2020 Feb; 295(7):2001-2017. PubMed ID: 31919096
[TBL] [Abstract][Full Text] [Related]
10. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
[TBL] [Abstract][Full Text] [Related]
11. MYC needs MNT.
Link JM; Hurlin PJ
Cell Cycle; 2013 Feb; 12(3):385-6. PubMed ID: 23324353
[No Abstract] [Full Text] [Related]
12. c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2α and promotes tumor angiogenesis and metastasis by upregulating FGF2.
Xue G; Yan HL; Zhang Y; Hao LQ; Zhu XT; Mei Q; Sun SH
Oncogene; 2015 Mar; 34(11):1393-406. PubMed ID: 24704828
[TBL] [Abstract][Full Text] [Related]
13. Mnt transcriptional repressor is functionally regulated during cell cycle progression.
Popov N; Wahlström T; Hurlin PJ; Henriksson M
Oncogene; 2005 Dec; 24(56):8326-37. PubMed ID: 16103876
[TBL] [Abstract][Full Text] [Related]
14. Induction, modulation and potential targets of miR-210 in pancreatic cancer cells.
Chen WY; Liu WJ; Zhao YP; Zhou L; Zhang TP; Chen G; Shu H
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):319-24. PubMed ID: 22672828
[TBL] [Abstract][Full Text] [Related]
15. Mnt modulates Myc-driven lymphomagenesis.
Campbell KJ; Vandenberg CJ; Anstee NS; Hurlin PJ; Cory S
Cell Death Differ; 2017 Dec; 24(12):2117-2126. PubMed ID: 28800127
[TBL] [Abstract][Full Text] [Related]
16. A dynamic exchange of TCF3 and TCF4 transcription factors controls MYC expression in colorectal cancer cells.
Shah M; Rennoll SA; Raup-Konsavage WM; Yochum GS
Cell Cycle; 2015; 14(3):323-32. PubMed ID: 25659031
[TBL] [Abstract][Full Text] [Related]
17. The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis.
Link JM; Hurlin PJ
Biochim Biophys Acta; 2015 May; 1849(5):554-62. PubMed ID: 24731854
[TBL] [Abstract][Full Text] [Related]
18. Mnt: a novel Max-interacting protein and Myc antagonist.
Hurlin PJ; Qúeva C; Eisenman RN
Curr Top Microbiol Immunol; 1997; 224():115-21. PubMed ID: 9308234
[TBL] [Abstract][Full Text] [Related]
19. MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1.
Wu Q; Yang Z; An Y; Hu H; Yin J; Zhang P; Nie Y; Wu K; Shi Y; Fan D
Cell Death Dis; 2014 Mar; 5(3):e1144. PubMed ID: 24675462
[TBL] [Abstract][Full Text] [Related]
20. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
Hurlin PJ; Quéva C; Eisenman RN
Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
